{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:26Z","timestamp":1790741546187,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-018-0580-2","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T01:09:26Z","timestamp":1520298566000},"page":"683-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Ruxolitinib + capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies"],"prefix":"10.1007","volume":"36","author":[{"given":"Herbert","family":"Hurwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Garrido","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Sama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Greeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Verslype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitzroy","family":"Dawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"key":"580_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7\u201330. https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"key":"580_CR2","unstructured":"NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma. Version 2.2017. National Comprehensive Cancer Network website http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 16 August 2017"},{"key":"580_CR3","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3748\/wjg.v20.i9.2224","volume":"20","author":"EJ Walker","year":"2014","unstructured":"Walker EJ, Ko AH (2014) Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol 20:2224\u20132236. https:\/\/doi.org\/10.3748\/wjg.v20.i9.2224","journal-title":"World J Gastroenterol"},{"key":"580_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545\u2013557. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"580_CR5","unstructured":"ONIVYDE\u00ae (irinotecan liposome injection) [package insert] (2015) Cambridge, Merrimack Pharmaceuticals, Inc"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109\u20133117. https:\/\/doi.org\/10.1182\/blood-2009-04-214957","journal-title":"Blood"},{"key":"580_CR7","unstructured":"JAKAVI\u00ae (ruxolitinib) [summary of product characteristics] (2016) Camberley, UK, Novartis Europharm Limited. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002464\/WC500133223.pdf. Accessed 8 May 2017"},{"key":"580_CR8","unstructured":"JAKAFI\u00ae (ruxolitinib) [package insert] (2016) Wilmington, DE, Incyte Corporation. http:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf. Accessed 8 May 2017"},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.18632\/oncotarget.3233","volume":"6","author":"J Gore","year":"2015","unstructured":"Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, Nguyen HV, Cramer HM, Sherman S, Korc M (2015) TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget 6:7504\u20137521. https:\/\/doi.org\/10.18632\/oncotarget.3233","journal-title":"Oncotarget"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/1538-7445.AM2015-1336","volume":"75","author":"HK Koblish","year":"2015","unstructured":"Koblish HK, Hansbury M, Wang L-CS, Yang G, Huang T, Xue C-B, Li Y-L, Yue E, Combs A, Yao W, Huber R, Scherle P (2015) Novel immunotherapeutic activity of JAK and PI3K\u03b4 inhibitors in a model of pancreatic cancer [abstract]. Cancer Res 75:1336. https:\/\/doi.org\/10.1158\/1538-7445.am2015-1336","journal-title":"Cancer Res"},{"key":"580_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kl\u00f6ppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Alg\u00fcl H (2011) Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456\u2013469. https:\/\/doi.org\/10.1016\/j.ccr.2011.03.009","journal-title":"Cancer Cell"},{"key":"580_CR12","doi-asserted-by":"publisher","unstructured":"Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE (2014) Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol 5(88). https:\/\/doi.org\/10.3389\/fphys.2014.00088","DOI":"10.3389\/fphys.2014.00088"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/10408363.2011.599831","volume":"48","author":"KH Allin","year":"2011","unstructured":"Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48:155\u2013170. https:\/\/doi.org\/10.3109\/10408363.2011.599831","journal-title":"Crit Rev Clin Lab Sci"},{"key":"580_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163064","volume":"11","author":"A Salmiheimo","year":"2016","unstructured":"Salmiheimo A, Mustonen H, Stenman U-H, Puolakkainen P, Kemppainen E, Sepp\u00e4nen H, Haglund C (2016) Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma. PLoS One 11:e0163064. https:\/\/doi.org\/10.1371\/journal.pone.0163064","journal-title":"PLoS One"},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00384-006-0259-6","volume":"22","author":"DC McMillan","year":"2007","unstructured":"McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Color Dis 22:881\u2013886. https:\/\/doi.org\/10.1007\/s00384-006-0259-6","journal-title":"Int J Color Dis"},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534\u2013540. https:\/\/doi.org\/10.1016\/j.ctrv.2012.08.003","journal-title":"Cancer Treat Rev"},{"key":"580_CR17","doi-asserted-by":"publisher","unstructured":"Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS (2015) Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33:4039\u20134047. https:\/\/doi.org\/10.1200\/JCO.2015.61.4578","DOI":"10.1200\/JCO.2015.61.4578"},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","volume":"20","author":"N Heffernan","year":"2002","unstructured":"Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L (2002) Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 20:2229\u20132239. https:\/\/doi.org\/10.1200\/JCO.2002.07.093","journal-title":"J Clin Oncol"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1002\/cncr.30927","volume":"123","author":"MB Sonbol","year":"2017","unstructured":"Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T (2017) Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Cancer 123:4680\u20134686. https:\/\/doi.org\/10.1002\/cncr.30927","journal-title":"Cancer"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/cco.2017.06.13","volume":"6","author":"P Cinar","year":"2017","unstructured":"Cinar P, Ko AH (2017) Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chin Clin Oncol 6:29. https:\/\/doi.org\/10.21037\/cco.2017.06.13","journal-title":"Chin Clin Oncol"},{"key":"580_CR21","doi-asserted-by":"publisher","unstructured":"Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M (2017) Second-line chemotherapy for advanced pancreatic cancer: which is the best option? Crit Rev Oncol Hematol 115:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.025","DOI":"10.1016\/j.critrevonc.2017.03.025"},{"key":"580_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pan.2015.04.004","volume":"15","author":"CW Imrie","year":"2015","unstructured":"Imrie CW (2015) Host systemic inflammatory response influences outcome in pancreatic cancer. Pancreatology 15:327\u2013330. https:\/\/doi.org\/10.1016\/j.pan.2015.04.004","journal-title":"Pancreatology"},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1245\/s10434-011-1560-3","volume":"18","author":"NB Jamieson","year":"2011","unstructured":"Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, Imrie CW, Carter R, McKay CJ, McMillan DC (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18:2318\u20132328. https:\/\/doi.org\/10.1245\/s10434-011-1560-3","journal-title":"Ann Surg Oncol"},{"key":"580_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.21037\/jgo.2017.02.02","volume":"8","author":"T Muranaka","year":"2017","unstructured":"Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N (2017) Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol 8:566\u2013571. https:\/\/doi.org\/10.21037\/jgo.2017.02.02","journal-title":"J Gastrointest Oncol"},{"key":"580_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM.S23277","volume":"8","author":"A Ostojic","year":"2012","unstructured":"Ostojic A, Vrhovac R, Verstovsek S (2012) Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 8:95\u2013103. https:\/\/doi.org\/10.2147\/TCRM.S23277","journal-title":"Ther Clin Risk Manag"},{"key":"580_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.gastro.2016.03.010","volume":"151","author":"SM W\u00f6rmann","year":"2016","unstructured":"W\u00f6rmann SM, Song L, Ai JY, Diakopoulos KN, Kurkowski MU, G\u00f6rg\u00fcl\u00fc K, Ruess D, Campbell A, Doglioni C, Jodrell D, Neesse A, Demir IE, Karpathaki AP, Barenboim M, Hagemann T, Rose-John S, Sansom O, Schmid RM, Protti MP, Lesina M, Alg\u00fcl H (2016) Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology 151:180\u2013193. https:\/\/doi.org\/10.1053\/j.gastro.2016.03.010","journal-title":"Gastroenterology"},{"key":"580_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1541-7786.MCR-16-0337","volume":"15","author":"JM Smigiel","year":"2017","unstructured":"Smigiel JM, Parameswaran N, Jackson MW (2017) Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer. Mol Cancer Res 15:478\u2013488. https:\/\/doi.org\/10.1158\/1541-7786.mcr-16-0337","journal-title":"Mol Cancer Res"},{"key":"580_CR28","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Hoffman R (2012) Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 18:3008\u20133014. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3145","journal-title":"Clin Cancer Res"},{"key":"580_CR29","first-page":"706","volume":"27","author":"M Kremyanskaya","year":"2013","unstructured":"Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO (2013) Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology 27:706\u2013714","journal-title":"Oncology"},{"key":"580_CR30","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.2174\/092986712803251511","volume":"19","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Mughal TI, Verstovsek S (2012) Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 19:4399\u20134413","journal-title":"Curr Med Chem"},{"key":"580_CR31","doi-asserted-by":"publisher","unstructured":"von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B (2013) Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther 8:193\u2013202. https:\/\/doi.org\/10.2174\/1574362409666140206221931","DOI":"10.2174\/1574362409666140206221931"},{"key":"580_CR32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"N Engl J Med"},{"key":"580_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","volume":"7","author":"H Yu","year":"2007","unstructured":"Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41\u201351. https:\/\/doi.org\/10.1038\/nri1995","journal-title":"Nat Rev Immunol"},{"key":"580_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley JJ (1982) A confidence interval for the median survival time. Biometrics 38:29\u201341","journal-title":"Biometrics"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0580-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:22:33Z","timestamp":1678558953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0580-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]},"assertion":[{"value":"21 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hurwitz: Honoraria \u2013 Genentech\/Roche, Lilly\/ImClone; Consulting or advisory role \u2013 Acceleron Pharma, Bristol-Myers Squibb, Genentech\/Roche, GlaxoSmithKline, Incyte, Lilly, Novartis, OncoMed, TRACON Pharma; Research funding \u2013 Bristol-Myers Squibb (Inst), Genentech\/Roche (Inst), GlaxoSmithKline (Inst), Lilly (Inst), Macrogenics (Inst), NCI (Inst), Novartis (Inst), Regeneron (Inst), TRACON Pharma (Inst); Employment \u2013 Genentech\/Roche as of 23 October 2017. Van Cutsem: Research funding \u2013 Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Celgene (Inst), Ipsen (Inst), Lilly (Inst), Merck Serono (Inst), Novartis (Inst), Roche (Inst), Sanofi (Inst). Bendell: Research funding \u2013 Incyte. Sahai: Consulting \u2013 Celgene, Halozyme, NewLink; Research funding \u2013 Agios (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Incyte (Inst). Sama: Honoraria \u2013 OncoPlex Diagnostics; Research funding \u2013 Bristol-Myers Squibb (Inst), Incyte (Inst), MedImmune (Inst), OncoMed (Inst), Precision Biologics (Inst); Employment \u2013 Bristol-Myers Squibb (Inst) as of March 20, 2017. Yu: Consulting or advisory role \u2013 Celgene, Merck Serono, Merrimack. Dawkins, Walker, Clark: Employment \u2013 Incyte; Stock and other ownership interests \u2013 Incyte. O\u2019Reilly: Consulting or advisory role \u2013 Aduro Biotech, Astellas Pharma (Inst), Celgene, Celsion (Inst), Cipla, Exelixis (Inst), Gilead Sciences, Hexal (Inst), IntegraGen (Inst), Jennerex (Inst), Lilly (Inst), MedImmune, Merrimack, Novartis (Inst), Pharmacyclics, Sanofi, Silenseed, Vicus Therapeutics; Research funding \u2013 AstraZeneca\/MedImmune (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Immunomedics (Inst), Incyte (Inst), Momenta Pharmaceuticals (Inst), Myriad Genetics (Inst), OncoMed (Inst), Polaris (Inst), Sanofi (Inst). Hidalgo, Li, Garrido, Macarulla, Greeno, Verslype: Nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}